Drug Type Peptide drug conjugates |
Synonyms MB 1707, MB1707, MLB-1707 |
Target |
Action antagonists |
Mechanism CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedEarly Phase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 1 | - | 01 Dec 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Dec 2022 | |
| Breast Cancer | Phase 1 | - | 01 Dec 2022 | |
| Non-Small Cell Lung Cancer | Phase 1 | - | 01 Dec 2022 | |
| Ovarian Cancer | Phase 1 | - | 01 Dec 2022 | |
| Pancreatic Cancer | Phase 1 | - | 01 Dec 2022 |





